Pseudoachondroplasia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:750OMIM:177170Q77.8
Who is this for?
Show terms as
2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Pseudoachondroplasia (PSACH) is a rare skeletal dysplasia characterized by disproportionate short stature, joint laxity, and early-onset osteoarthritis. It is sometimes referred to as pseudoachondroplastic dysplasia or pseudoachondroplastic spondyloepiphyseal dysplasia. Unlike achondroplasia, individuals with pseudoachondroplasia have normal facial features and head size. The condition is caused by mutations in the COMP (cartilage oligomeric matrix protein) gene located on chromosome 19p13.1, which encodes a protein essential for normal cartilage and bone development. The disease is typically not apparent at birth, with affected children appearing normal in length and proportions. Short stature and limb shortening usually become noticeable around age 2 to 3 years, when the child begins walking and growth deceleration becomes evident. Key skeletal features include short limbs (particularly the proximal segments), a waddling gait, lumbar lordosis (exaggerated inward curvature of the lower back), brachydactyly (short fingers), and generalized joint hypermobility, particularly at the knees and fingers. Windswept deformity of the legs (valgus or varus angulation at the knees) is common. Spinal abnormalities may include platyspondyly (flattened vertebral bodies) and anterior beaking of vertebrae. Adult height typically ranges from approximately 82 to 130 cm (about 2.7 to 4.3 feet). Early-onset osteoarthritis, particularly affecting the hips and knees, is a significant source of morbidity and pain, often requiring joint replacement surgery in adulthood. There is currently no cure or disease-modifying therapy for pseudoachondroplasia. Management is supportive and multidisciplinary, focusing on orthopedic surveillance and intervention. Treatment may include surgical correction of lower limb malalignment, management of spinal complications, physical therapy to maintain joint function and muscle strength, and pain management for osteoarthritis. Limb-lengthening procedures may be considered in some cases. Regular monitoring by an orthopedic specialist experienced in skeletal dysplasias is recommended throughout life. Genetic counseling is important for affected individuals and their families.

Also known as:

Clinical phenotype terms— hover any for plain English:

Disproportionate short-limb short statureHP:0008873Delayed epiphyseal ossificationHP:0002663Generalized joint hypermobilityHP:0002761Metaphyseal wideningHP:0003016Metaphyseal irregularityHP:0003025Shortening of all metacarpalsHP:0005720Increased laxity of fingersHP:0006149Short phalanx of fingerHP:0009803Irregular epiphysesHP:0010582Distal joint hypermobilityHP:0020152
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Pseudoachondroplasia.

View clinical trials →

No actively recruiting trials found for Pseudoachondroplasia at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Pseudoachondroplasia community →

Specialists

2 foundView all specialists →
AP
Achmad Zaki, PhD
Specialist
PI on 1 active trial
KP
Karen Posey
HALLSVILLE, TX
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Pseudoachondroplasia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open PseudoachondroplasiaForum →

No community posts yet. Be the first to share your experience with Pseudoachondroplasia.

Start the conversation →

Latest news about Pseudoachondroplasia

No recent news articles for Pseudoachondroplasia.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Pseudoachondroplasia

What is Pseudoachondroplasia?

Pseudoachondroplasia (PSACH) is a rare skeletal dysplasia characterized by disproportionate short stature, joint laxity, and early-onset osteoarthritis. It is sometimes referred to as pseudoachondroplastic dysplasia or pseudoachondroplastic spondyloepiphyseal dysplasia. Unlike achondroplasia, individuals with pseudoachondroplasia have normal facial features and head size. The condition is caused by mutations in the COMP (cartilage oligomeric matrix protein) gene located on chromosome 19p13.1, which encodes a protein essential for normal cartilage and bone development. The disease is typically

How is Pseudoachondroplasia inherited?

Pseudoachondroplasia follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Pseudoachondroplasia typically begin?

Typical onset of Pseudoachondroplasia is childhood. Age of onset can vary across affected individuals.

Which specialists treat Pseudoachondroplasia?

2 specialists and care centers treating Pseudoachondroplasia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.